We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
New hepatitis C treatments were the biggest driver of specialty drug spending growth in the U.S. last year, helping to push total outlays on prescription drugs to $374 billion, the IMS Health Institute for Healthcare Informatics reports. Read More
AstraZeneca is catching the clinical trial transparency wave, creating a new scientific review board to evaluate requests for the company’s data. Read More
Baxter International issued its sixth recall of intravenous solutions since December 2013, recalling 15 lots — about 237,000 units — because of the potential presence of particulate matter. Read More
The Federal Trade Commission Wednesday approved Novartis’ divestiture of its targeted cancer drug business, clearing the way for a portfolio swap with GlaxoSmithKline valued at $21 billion. Read More
The FDA’s Office of Prescription Drug Promotion wants to know how consumers perceive drugmakers’ comparisons of pricing and efficacy information in advertisements. Read More